NervGen Pharma Price To Book vs. Shares Owned By Insiders
| NGEN Stock | CAD 2.90 0.10 3.33% |
For NervGen Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NervGen Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NervGen Pharma Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NervGen Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NervGen Pharma Corp over time as well as its relative position and ranking within its peers.
NervGen |
NervGen Pharma Corp Shares Owned By Insiders vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NervGen Pharma's current stock value. Our valuation model uses many indicators to compare NervGen Pharma value to that of its competitors to determine the firm's financial worth. NervGen Pharma Corp is regarded second in price to book category among its peers. It is considered to be number one stock in shares owned by insiders category among its peers making about 1.03 of Shares Owned By Insiders per Price To Book. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the NervGen Pharma's earnings, one of the primary drivers of an investment's value.NervGen Shares Owned By Insiders vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
NervGen Pharma |
| = | 22.22 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
NervGen Pharma |
| = | 22.91 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
NervGen Shares Owned By Insiders Comparison
NervGen Pharma is currently under evaluation in shares owned by insiders category among its peers.
NervGen Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NervGen Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NervGen Pharma will eventually generate negative long term returns. The profitability progress is the general direction of NervGen Pharma's change in net profit over the period of time. It can combine multiple indicators of NervGen Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 13.6 M | 14.3 M | |
| Operating Income | -17.8 M | -16.9 M | |
| Net Loss | -22.4 M | -21.3 M | |
| Income Before Tax | -22.4 M | -21.3 M | |
| Net Loss | -18.7 M | -17.7 M | |
| Net Loss | -22.4 M | -21.3 M | |
| Net Interest Income | 550.1 K | 577.6 K | |
| Interest Income | 550.1 K | 577.6 K | |
| Total Other Income Expense Net | -5.2 M | -4.9 M | |
| Income Tax Expense | -2.4 M | -2.2 M | |
| Change To Netincome | 814.3 K | 773.5 K | |
| Net Loss | (0.38) | (0.40) | |
| Income Quality | 0.50 | 0.77 | |
| Net Income Per E B T | 1.00 | 1.06 |
NervGen Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NervGen Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NervGen Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NervGen Pharma's important profitability drivers and their relationship over time.
Use NervGen Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NervGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NervGen Pharma will appreciate offsetting losses from the drop in the long position's value.NervGen Pharma Pair Trading
NervGen Pharma Corp Pair Trading Analysis
The ability to find closely correlated positions to NervGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NervGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NervGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NervGen Pharma Corp to buy it.
The correlation of NervGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NervGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NervGen Pharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NervGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your NervGen Pharma position
In addition to having NervGen Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alternative Energy Thematic Idea Now
Alternative Energy
Large and mid-size companies, ETFs and funds that are either investing or directly involved in providing energy derived from sources not connected to fossil fuels, do not consume natural resources, and do not harm the environment. This includes wind power, nuclear and solar energy, biofuel, ethanol, hydrogen and others alternative sources of energy. The Alternative Energy theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Energy Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.